Biotech Startups
9,585 companies tagged Biotech, with their investors and founders.
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries. The company combines scientific rigor with global partnerships and licensing programs to expand access to medicines worldwide.
12 investors
One Health operates a clinical trial platform using canine cancer data to accelerate and de-risk human oncology drug development. The company leverages a dataset of 2 billion datapoints from dogs with naturally occurring cancer to serve as a comparative model for pharmaceutical R&D, helping drug developers validate efficacy and identify biomarkers before human trials.
12 investors
Finless Foods develops cell-cultivated seafood alternatives, starting with Pacific bluefin tuna, aimed at consumers seeking sustainable options that reduce pressure on wild fish stocks. The company uses cellular agriculture to produce cultured fish for the consumer food market.
12 investors
Guardant Health develops blood-based testing (liquid biopsy) for cancer detection and monitoring across all stages of the disease. The company serves oncologists, patients, and biopharmaceutical firms with FDA-approved tests for cancer screening, early-stage risk assessment, and treatment selection.
12 investors
Insilico Medicine applies computational and AI-based modeling to drug design and problems such as protein folding for pharmaceutical research and development. The company operates in the biotechnology and drug discovery sector.
12 investors
Iterative Health is a healthcare technology and services company that combines clinical trial expertise with AI to help research teams and study sponsors expand and speed up patients' access to novel therapeutics. It partners with providers and study sponsors to support clinical research infrastructure, particularly in gastroenterology and community care settings.
12 investors
Living Carbon develops precision-bred tree varieties and reforestation techniques to convert marginal land into carbon-sequestering ecosystems. The company targets climate mitigation through enhanced photosynthesis and biodiversity restoration.
12 investors
Opentrons develops laboratory robots that automate scientific research tasks for scientists and research institutions. The company aims to democratize access to laboratory automation and increase the availability of robotic systems to accelerate discovery in life sciences.
12 investors
Tropic develops improved varieties of tropical crops using gene editing and gene silencing technologies to enhance yield, disease resistance, and climate resilience. The company serves farmers and global consumers by creating staple crops like bananas and rice that reduce pesticide dependency and environmental impact.
12 investors
Unnatural Products is a drug discovery platform company that develops synthetic macrocycles to target previously undruggable disease targets. The company focuses on expanding its pipeline of novel therapeutic medicines by leveraging macrocycle chemistry and pharmacokinetics.
12 investors
Aether develops additives that blend into engineering-grade nylons to enable faster, high-throughput fused filament (FFF/FDM) 3D printing while maintaining mechanical strength and dimensional accuracy. Its products serve additive manufacturing users in production, field repair, and prototyping settings.
11 investors
AtaiBeckley develops rapid-acting mental health treatments and therapies for patients with difficult-to-treat mental health conditions. The company was founded in 2025 through a strategic combination of atai Life Sciences and Beckley Psytech.
11 investors
Evidation collects and analyzes real-world health data from millions of community members to enable clinical research and health programs across various medical conditions. The platform partners with healthcare organizations, biomedical firms, government agencies, and nonprofits to drive discoveries and inform healthcare decision-making using everyday health data.
11 investors
Gilgamesh Pharmaceutical develops novel chemical entities for psychiatric disorders using medicinal chemistry and AI-powered translational platforms to design rapid-acting therapies targeting neurobiological mechanisms rather than symptom management. The company's pipeline spans depression, anxiety, addiction, and schizophrenia, with programs validated by AbbVie's acquisition of its first asset and partnerships with Columbia University and the National Institute on Drug Abuse.
11 investors
LabGenius develops EVA, an automated discovery engine for identifying and co-optimizing complex therapeutic antibodies such as multispecifics across multiple properties. Its internal pipeline focuses on selectivity-enhanced antibodies for treating solid tumours.
11 investors
NewLimit develops epigenetic reprogramming medicines to extend healthspan and treat age-related diseases at the intersection of computer science and biotechnology. The company builds therapeutic programs that aim to engineer cell identity and reprogram cell age for human patients.
11 investors
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation. Its pipeline focuses on autoimmune and inflammatory diseases with large patient populations and unmet medical need.
11 investors
Recursion applies artificial intelligence and large-scale data analysis to accelerate drug discovery and development. The company develops therapeutics for patients waiting for new treatment options by industrializing pharmaceutical research through automation and computational biology.
11 investors
Resilience is a contract development and manufacturing organization (CDMO) that manufactures complex pharmaceutical products and active pharmaceutical ingredients to broaden access to medicines and protect biopharmaceutical supply chains against disruption.
11 investors
Alentis Therapeutics is a clinical-stage biotech company developing anti-Claudin-1 antibody-drug conjugates (ADCs) and monoclonal antibodies to treat cancer and reverse organ fibrosis. Its clinical pipeline includes the ADC ALE.P02 for squamous cancers and the monoclonal antibody lixudebart for organ fibrosis.
10 investors
Aspect Biosystems is a Canadian biotechnology company developing Bioprinted Tissue Therapeutics—implantable engineered tissues designed to replace, repair, or supplement biological function—for the treatment of diseases such as type 1 diabetes. It operates in the regenerative medicine field and has partnered with pharmaceutical companies including Novo Nordisk.
10 investors
Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors. Its lead focus is treating choroidal melanoma, a rare ocular cancer for which no first-line drug therapies currently exist.
10 investors
Axonis Therapeutics is a drug discovery company developing first-in-class therapies for currently incurable neurological disorders. It focuses on advancing treatments for patients with neurological diseases.
10 investors
Debut develops an AI-powered biomanufacturing platform that uses genomics and biotechnology to discover, validate, and scale novel bioactive ingredients for the beauty industry, including skincare, hair, and body care products. It operates a vertically integrated model with San Diego facilities and supplies formulations to beauty brand partners worldwide, and also runs its own consumer brand, DEINDE.
10 investors